Estrogen plays a significant role in human ovulation. It acts as an important positive regulator of the preovulatory gonadotropin surge necessary to initiate the cascade of events leading to ovulation. The steroid hormone exerts its physiological responses through the estrogen receptor (ER), of which two subtypes, ER␣ and ER␤, are known. ER␤ messenger ribonucleic acid occurs maximally in the ovaries and granulosa cells; thus, ER␤ may be essential for normal ovulation. In a recent gene knockout study, it has been shown that ER␤ gene null female mice develop normal reproductive tract and ovaries during pre-and neonatal periods, but have an abnormal frequency of spontaneous ovulation in adulthood. In the present casecontrol study, we explored the association of two recently described ER␤ gene polymorphisms, RsaI and AluI, with ovulatory dysfunctions. The respective frequencies of these polymorphisms were significantly higher in patients than in controls (P ϭ 0.009 and P ϭ 0.059). The polymorphisms were significantly associated with ovulatory dysfunctions, especially in patients homozygous for the polymorphisms (P ϭ 0.016 and P ϭ 0.038, respectively). The compound homozygosity of the polymorphisms was seen only in patients (n ϭ 5) and not controls (P ϭ 0.009). The serum levels of LH, FSH, and progesterone were lower in the homozygous and compound homozygous than in the respective nonpolymorphic patients. All five compound homozygous patients had ovulatory dysfunctions with no etiological pathology. Our results suggest that ER␤ gene RsaI and AluI polymorphisms may be associated with ovulatory defects in some patients, especially those with unknown causes. (J Clin Endocrinol Metab 86: [135][136][137][138][139] 2001) 
H UMAN OVULATION requires the interaction of the central nervous system (primarily the hypothalamus), pituitary gland, and ovary, in which estrogen plays an important role (1) . This steroid hormone produced in the ovaries controls the secretion of pituitary gonadotropins and is a key intraovarian modulator of ovarian activity, principally affecting the function of granulosa cells. It contributes to oocyte maturation, fertilization, and embryo quality (2) . It also participates in stimulating antral and preantral follicular growth, which may be mediated by insulin-like growth factors (3) .
Estrogen triggers a broad array of tissue-and organspecific physiological responses by binding to a nuclear receptor protein, the estrogen receptor (ER). The ER is classified as a class 1 member of the superfamily of nuclear hormone receptors, defined as ligand-inducible transcription factors (4) . ERs have been identified in the human oocyte (5) , granulosa cells (6) , and ovarian epithelial cells (7) . Two subtypes of ER are now known, ER␣ and ER␤ (8) . Both ER␣ and ER␤ genes are expressed in the human ovary (7, 9) .
Recent findings strongly suggest that ER␣ polymorphisms may be associated with the outcome of in vitro fertilization and pregnancy rates (10, 11) . They may cause a phenotypic disadvantage to patients undergoing ovarian hyperstimulation. Previously, Hill et al. (12) reported an association between ER polymorphisms and ER expression in human breast cancer. Moreover, it has recently been observed that a polymorphism in the CYP17 gene involved in estrogen synthesis could create an additional promoter site in the gene and influence production of the hormone (13) .
Although polymorphisms may not be directly linked to a certain disease, they may be useful tools in the study of multifactorial disorders (14, 15) . Moreover, association studies of the polymorphisms may be meaningful when applied to genes with a clear biological significance in the disorder (16) . Single nucleotide polymorphisms (SNPs) are the most frequently found DNA sequence variations in the human genome (17) . There is now considerable interest in the discovery and characterization of SNPs to enable the analysis of potential relationships between genotypes and phenotypes (18) .
As ER␤ messenger ribonucleic acid (mRNA) occurs maximally in ovaries and granulosa cells (8) , the ER␤ gene is likely to have a role in ovulatory function. A recent ER␤ knockout study in female mice has confirmed that ER␤ is essential for normal ovulation efficiency, but not for sexual differentiation, fertility, or lactation (19) .
Recently, several genetic variants of ER␤ gene were described, with evidence of the highest incidence of RsaI and AluI polymorphisms in the probands of different weight extremes in the German population (20) . In this study the significance of these common ER␤ polymorphisms, RsaI and AluI, in ovulatory dysfunction was evaluated.
Subjects and Methods Subjects
Ninety-eight local Chinese women with ovulation defects and menstrual disorders attending the National University Hospital, Singapore, were recruited for this study. Their age ranged from 14 -39 yr (mean Ϯ sd, 25.6 Ϯ 6.71 yr). Serum progesterone (P) values less than 31.8 nmol/L confirmed the deranged ovulatory status in all the patients. Of 98 patients, 33 showed ovulation disturbances of unknown causes (idiopathic), 30 had associated polycystic ovary syndrome (PCOS), 13 had ovulatory defects because of reproductive causes (premature ovarian failure, gonadal dysgenesis, resistant ovarian syndrome, fibroids, and ovarian endometrial cyst), and 22 showed ovulatory defects of nonreproductive causes (hyperthyroidism, hypothyroidism, diabetes, malnutrition, exercise, stress, and obesity).
One hundred and fifty apparently healthy local Chinese women, aged 18 -44 yr (mean Ϯ sd[scap], 32.7 Ϯ 4.56 yr) with spontaneous regular menstrual cycles (intervals between 23 and 39 days) were used as control subjects. They had normal ovulatory cycles, as indicated by serum P levels (Ͼ10 ng/mL) measured during the ovulatory and midluteal phases. Informed consent of the patients and approval of the study by the ethical committee were obtained.
PCR
Nuclear DNA was extracted from the peripheral leukocytes by a standard procedure. The ligand binding domain of exon 5 and the 3Ј-untranslated region of exon 8 of the ER␤ gene were amplified using the following primers: A, 5Ј-TCTTGCTTTCCCCAGGCTTT-3Ј; B, 5Ј-ACCTGTCCAGAACAAGATCT-3Ј; C, 5Ј-TTTTTGTCCCCATAGTA-ACA-3Ј; and D, 5Ј-AATGAGGGACCACAGCA-3Ј, respectively. Amplification using the PCR technique was performed for 40 cycles at an annealing temperature of 52 C as described previously (21) . Amplification of exons 5 and 8 yielded the desired products of 156 and 307 bp, respectively.
Restriction fragment length polymorphism (RFLP)
The PCR products were analyzed for RFLP using RsaI and AluI restriction enzymes as described previously (22) . Nucleotide exchange G-A at nucleotide 1082 in exon 5 created a recognition site for RsaI, and exchange at nucleotide 1730 in exon 8 introduced a recognition site for AluI. G at nucleotide 1730 was considered the wild-type sequence, because it was detected predominantly in the studied population.
Serum levels of estradiol (E 2 ), P, testosterone (T), LH, and FSH were measured by their specific RIAs using reagents provided by WHO under the Matched Reagent Program (23) .
Statistical analysis
The Hardy-Weinberg equilibrium was estimated by the 2 test, and all serum values were subjected to one-way ANOVA to achieve homogeneity of variance. Statistical tests of significance and 2 analysis were carried out using SPSS for Windows 8.0 (SPSS, Inc., Chicago, IL). P Ͻ 0.05 was considered statistically significant.
Results
RsaI digestion yielded one band of 156 bp in the normal ER␤ sequence (rr); three separate bands of 156, 125, and 31 bp in the heterogeneous polymorphism (Rr); and two separate bands of 125 and 31 bp in the homozygous polymorphism (RR; Fig. 1A ).
AluI digestion produced one band of 307 bp in the normal ER␤ sequence (aa); three separate bands of 307, 240, and 67 bp in the heterozygous polymorphism (Aa); and two separate bands of 240 and 67 bp in the homozygous polymorphism (AA; Fig. 1b) .
The respective incidence of RsaI and AluI genotypes in 98 patients and 150 control subjects is shown in Table 1 . The respective frequency of RsaI and AluI polymorphisms was significantly higher in patients than controls (P ϭ 0.009; 2 ϭ 9.517 and P ϭ 0.059; 2 ϭ 5.671, respectively). The occurrence of respective homozygous RsaI and AluI polymorphisms was also significantly higher in patients (8.2% and 11.2%) than in controls (1.3% and 4%; P ϭ 0.016 and P ϭ 0.038; Table 1 ). Interestingly, compound homozygosity of the polymorphisms was seen only in the patients (n ϭ 5) and not in the controls (P ϭ 0.009). Furthermore, the respective frequency of RsaI and AluI polymorphisms was significantly higher in idiopathic patients than controls (P Ͻ 0.001; 2 ϭ 23.19 and P Ͻ 0.001; 2 ϭ 17.160, respectively). The respective occurrence of homozygous RsaI and AluI polymorphisms was also significantly higher in idiopathic patients than controls (P Ͻ 0.001 and P ϭ 0.001; Table 1 ). All five compound homozygous patients presented ovulatory dysfunctions of unknown causes (P Ͻ 0.001). The frequency of RsaI polymorphism, but not of AluI polymorphism, was significantly higher in PCOS patients than controls (P ϭ 0.019 and P ϭ 0.568, respectively).
Serum levels of E 2 , P, T, LH, and FSH in patients of various genotypes (rr, Rr, RR, aa, Aa, AA, RR-AA, and rr-aa) are given in Table 2 . Serum levels of E 2 and T did not show any significant differences in patients among the three genotypes of RsaI polymorphism (0.828 Յ P Յ 1.000), AluI polymorphism (0.151 Յ P Յ 0.886), and RR-AA and rr-aa genotypes (0.456 Յ P Յ 0.714).
Serum levels of LH were lower in the RsaI homozygous (5.01 IU/L) than in the corresponding nonpolymorphic (7.41 IU/L) patients, but the difference was not statistically significant (P ϭ 0.440). Similarly, they were lower in the AluI homozygous (4.58 IU/L) than in the corresponding nonpolymorphic patients (8.53 IU/L; P ϭ 0.050). However, they were significantly lower in the patients compound homozygous for both RsaI and AluI polymorphisms (3.46 IU/L) than in those carrying no polymorphisms (8.26 IU/L; P ϭ 0.004).
Serum levels of P in the RsaI homozygous (1.72 nmol/L), AluI homozygous (2.45 nmol/L), and compound homozygous for both polymorphisms (0.80 nmol/L) were significantly lower than those in the respective nonpolymorphic patients (rr, 7.85 nmol/L; aa, 8.90 nmol/L; rr-aa, 7.73 nmol/L; P Ͻ 0.001).
Serum levels of FSH were slightly lower in the RsaI homozygous (2.89 IU/L) than in the corresponding nonpolymorphic patients (3.76 IU/L; P ϭ 0.822). They were also lower in the AluI homozygous (2.53 IU/L) than in the corresponding nonpolymorphic (4.75 IU/L) patients (P ϭ 0.093). For the patients homozygous for both RsaI and AluI polymorphisms (2.06 IU/L), FSH levels were lower than those in the patients without these polymorphisms (4.19 IU/L), but the difference was not statistically significant (P ϭ 0.221). Clinical and endocrinological profiles of the patients compound homozygous for both polymorphisms are shown in Table 3 .
In PCOS patients, there were no significant differences in the serum levels of these hormones among the genotypes of polymorphisms (data not shown).
Discussion
Ovulation is a complex process that requires interrelated actions of LH, FSH, estrogen, and P. Hormonal and follicular factors have been implicated in the initiation of the cascade of events leading to ovulation (24, 25) . The preovulatory gonadotropin surge, which is closely related to ovulation, initiates the first oocyte meiotic division. Ovarian-derived estrogen plays an important role as a positive regulator of the preovulatory gonadotropin surge (26) . It also increases its own receptor levels in granulosa cells of the growing follicles (27) and attenuates apoptosis and follicular atresia (28) . The steroid hormone induces the proliferation of granulosa cells and increases the sensitivity of the follicle to further gonadotropin stimulation. In addition, it enhances the responsiveness of granulosa cells to FSH and LH by increasing P synthesis. Estrogen is also known to augment the actions of FSH on granulosa cells and enhance gonadotropin stimulation of FSH and LH receptors in granulosa cells (29) , which are critical to successful ovulation (30, 31) . Therefore, estrogen is included in two positive feedback loops, one at the pituitary and one at the ovary, to maintain the dominant follicle and ensure ovulation. Thus, normal ovarian function depends on a multitude of auto-and paracrine effects of estrogen. It acts in concert with the gonadotropins secreted from the anterior pituitary and provides successful folliculogenesis and an intrafollicular steroid environment, which are essential for the development and maturation of oocytes. Alternations in the steroid profile during maturation induce changes in the oocyte that affect the fertilization process (32, 33) .
The study of ER␤ null female mice (19) suggested that reduced ovulation efficiency could be primarily due to a defect within ovarian tissue, more precisely an inability of E 2 to exert its effect on the granulosa cells of maturing follicles. An impaired ability to produce an adequate gonadotropin surge was also considered to be a contributing factor to the decreased ovulation rate (34) .
In this case-control study, the incidence of homozygous RsaI polymorphism and AluI polymorphism was higher in patients than controls. Moreover, the coexistence of RsaI and AluI homozygosity was seen only in the patients (n ϭ 5) and not in the controls. In addition, 6 of 8 patients homozygous for RsaI, 8 of 11 patients homozygous for AluI, and all 5 patients homozygous for both RsaI and AluI polymorphisms were found to have ovulatory defects of unknown causes. These results suggest that homozygous RsaI and AluI polymorphisms may be associated with ovulatory dysfunctions, especially in patients with no known causes of the dysfunctions. Interestingly, the frequency of RsaI polymorphism was significantly higher in PCOS patients than controls. However, this finding in the PCOS patients needs to be confirmed in a separate study involving a large number of patients.
In this study gradient patterns of LH and P levels were observed in the patients carrying homozygous and compound homozygous polymorphisms. Serum levels of these hormones were apparently lower in homozygous and compound homozygous patients than in their respective nonpolymorphic counterparts; these were lower in the compound homozygous than in the homozygous patients. It is possible that in ovarian tissue where the hormones and their respective receptors coexist, some loss of ER␤ action occurs in the homozygous patients, which is greater in the compound homozygous subjects. This, in turn, results in an alteration in the generation and/or function of other hormones, such as LH and P (34). Serum FSH levels showed an apparent gradient pattern without statistical significance.
Although serum E 2 levels were low in all patients, these were within the normal range of the hormone. The female mice lacking ER␤ also showed normal serum E 2 levels (19), indicating that the biosynthesis of estrogen was within normal limits.
Like ER␣, ER␤ is also present in various regions of the hypothalamus (35) . E 2 was shown to induce GnRH release from the hypothalamus as well as increase the level of GnRH receptors in the anterior pituitary (26) . It is likely that a lack of hypothalamic ER␤ function reduces the positive regulatory effect of E 2 on the hypothalamic-pituitary axis, causing a reduction in the frequency and/or amplitude of the preovulatory gonadotropin surge and, hence, defective ovulation (34) . The reduction in the preovulatory gonadotropin surge may also account for the decreased levels of LH and, to some extent, of FSH in the polymorphic homozygous patients.
Although RsaI and AluI polymorphisms in the ER␤ gene do not lead to amino acid changes in the ER␤ protein, it is possible that these polymorphisms are in linkage disequilibrium with other regulatory sequence variations that may affect gene expression or function (36) . It is now becoming increasingly clear that SNPs, the most frequently found sequence variations in DNA in the human genome, may be useful as markers for the identification of genetic factors associated with complex disease traits (17) . Furthermore, it has been recently reported that genes containing SNPs can cause different structural folds of mRNA (37) . These mRNA variants may possess different biological functions that interact with other cellular components.
In conclusion, in this case-control study significant associations of the homozygous RsaI and AluI polymorphisms with ovulatory dysfunctions were seen. Serum levels of LH, P, and, to a lesser extent, FSH showed gradient patterns in the patients homozygous and particularly in those com- pound homozygous for RsaI and AluI, polymorphisms. Interaction of environmental factors with a small number of major causative genes including those involved in paracrine and autocrine modifications of ovulatory functions may contribute to these associations. Thus, our study, the first of its kind in this area, postulates that genetic variability of the ER␤ gene may be associated with ovulatory dysfunction, especially that of unknown cause.
